Why is Suven Life Sciences Ltd falling/rising?

Recent Price Movement and Market Performance

Suven Life Sciences has experienced a sharp downturn over the past month, with its stock price declining by 23.04%, significantly underperforming the Sensex benchmark, which fell by only 3.74% during the same period. Year-to-date, the stock has lost 23.40%, compared to the Sensex's 3.95% decline. Even in the short term, the stock has been on a downward trajectory, falling for two consecutive days and registering a 6.65% loss in that span. Intraday trading on 27-Jan saw the stock touch a low of ₹125.90, down 5.69%, with heavier volumes concentrated near this lower price point, signalling selling pressure.

Technical indicators further underscore the bearish sentiment. Suven Life Sciences is trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, suggesting a sustained downtrend. Additionally, investor participation appears to be waning, as delivery volumes on 23-Jan dropped by 25.79% compared to the five-day average, indicating reduced buying interest from shareholders.

Fundamental Weaknesses Weighing on the Stock

Underlying the recent price decline are significant fundamental challenges. Over the past five years, Suven Life Sciences has reported negative growth in net sales, shrinking at an annual rate of 23.11%. Operating profits have deteriorated even more sharply, declining by 186.11% annually over the same period. This poor financial trajectory has undermined the company’s long-term growth prospects and investor confidence.

The company’s ability to service its debt is also concerning, with an average EBIT to interest ratio of -149.78, indicating that earnings before interest and taxes are insufficient to cover interest expenses. This weak debt servicing capacity adds to the risk profile of the stock.

Moreover, Suven Life Sciences has reported negative results for five consecutive quarters. The profit before tax excluding other income for the latest quarter stood at a loss of ₹81.09 crores, a 69.2% decline compared to the average of the previous four quarters. Similarly, the net profit after tax for the quarter was a loss of ₹77.31 crores, down 67.9% from the prior four-quarter average. Operating cash flow for the year has also been negative, with the lowest recorded figure at ₹47.39 crores, further highlighting operational difficulties.

The company’s earnings before interest, taxes, depreciation, and amortisation (EBITDA) remain negative, signalling ongoing operational losses. Despite the stock generating a 10.51% return over the past year, profits have fallen by 45.2%, reflecting a disconnect between market performance and underlying financial health. This disparity suggests that the stock is trading at risky valuations relative to its fundamentals.

Investor Sentiment and Outlook

Investor sentiment towards Suven Life Sciences remains cautious due to the company’s sustained losses and weak financial metrics. The stock’s liquidity is adequate for moderate trade sizes, but the falling delivery volumes indicate a decline in active investor participation. Promoters remain the majority shareholders, but the persistent negative earnings and operating losses have overshadowed any potential confidence boost from promoter holding.

In summary, the recent fall in Suven Life Sciences’ share price is primarily driven by its deteriorating financial performance, negative earnings over multiple quarters, and weak operational cash flows. The stock’s underperformance relative to the broader market and sector benchmarks further reflects investor concerns about the company’s long-term viability and growth prospects. Until there is a clear turnaround in fundamentals and profitability, the stock is likely to remain under pressure.

Limited Time Only! Subscribe for Rs. 12,999 and get 1 Year of MojoOne + an Additional Year Completely FREE. Don't miss out on this exclusive offer. Claim Your Free Year →